within Pharmacolibrary.Drugs.ATC.L;

model L04AE02
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.94,
    Cl             = 0.0038333333333333336,
    adminDuration  = 600,
    adminMass      = 1 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 5.59,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.005166666666666667,
    Tlag           = 30.0,            
    Vdp             = 3.64,
    k12             = 171,
    k21             = 171
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L04AE02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Ozanimod is an oral sphingosine 1-phosphate receptor modulator used primarily for the treatment of relapsing forms of multiple sclerosis (MS) and moderately to severely active ulcerative colitis. It reduces the migration of lymphocytes into the central nervous system, decreasing inflammatory damage. Ozanimod is a currently approved and marketed drug.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics model parameters reported after oral administration of single or multiple doses (1 mg) in healthy adult subjects.</p><h4>References</h4><ol><li><p>Tran, JQ, et al., &amp; Palmisano, M (2020). Single-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites Alone and in Combination with Gemfibrozil, Itraconazole, or Rifampin in Healthy Subjects: A Randomized, Parallel-Group, Open-Label Study. <i>Advances in therapy</i> 37(10) 4381–4395. DOI:<a href=&quot;https://doi.org/10.1007/s12325-020-01473-0&quot;>10.1007/s12325-020-01473-0</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32857315/&quot;>https://pubmed.ncbi.nlm.nih.gov/32857315</a></p></li><li><p> (2020). Ozanimod (Zeposia) for multiple sclerosis. <i>The Medical letter on drugs and therapeutics</i> 62(1605) 132–134. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32970043/&quot;>https://pubmed.ncbi.nlm.nih.gov/32970043</a></p></li><li><p>Rowan, C, et al., &amp; Colombel, JF (2022). An overview of ozanimod as a therapeutic option for adults with moderate-to-severe active ulcerative colitis. <i>Expert opinion on pharmacotherapy</i> 23(8) 893–904. DOI:<a href=&quot;https://doi.org/10.1080/14656566.2022.2071605&quot;>10.1080/14656566.2022.2071605</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35503955/&quot;>https://pubmed.ncbi.nlm.nih.gov/35503955</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L04AE02;
